BrightSpring Health Services, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US10950A1060
USD
40.30
0.31 (0.78%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.41 M

Shareholding (Sep 2025)

FII

8.14%

Held by 82 FIIs

DII

0

Held by 66 DIIs

Promoter

49.87%

How big is BrightSpring Health Services, Inc.?

22-Jun-2025

As of Jun 18, BrightSpring Health Services, Inc. has a market capitalization of $3.75 billion, with recent net sales of $11.57 billion and a net profit of $35.08 million.

Market Cap: As of Jun 18, BrightSpring Health Services, Inc. has a market capitalization of 3,753.42 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, BrightSpring Health Services, Inc. reported net sales of 11,567.96 million and a net profit of 35.08 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,647.86 million and total assets of 6,198.23 million.

View full answer

What does BrightSpring Health Services, Inc. do?

22-Jun-2025

BrightSpring Health Services, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $2.878 billion and a net profit of $9 million. Key metrics include a market cap of $3.75 billion, a P/E ratio of 37.00, and a debt-to-equity ratio of 1.50.

Overview: <BR>BrightSpring Health Services, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2,878 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 9 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,753.42 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 37.00 <BR>Debt Equity: 1.50 <BR>Return on Equity: 6.69% <BR>Price to Book: 2.22<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

View full answer

Should I buy, sell or hold BrightSpring Health Services, Inc.?

22-Jun-2025

Is BrightSpring Health Services, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, BrightSpring Health Services, Inc. shows a bullish technical trend with strong momentum indicators, despite a mildly bearish weekly KST, and has significantly outperformed the S&P 500 over the past year.

As of 3 September 2025, the technical trend for BrightSpring Health Services, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the weekly KST is mildly bearish, which suggests some caution. The Dow Theory indicates a bullish trend on the monthly timeframe, while the OBV is bullish on the monthly as well.<BR><BR>In terms of performance, BrightSpring has outperformed the S&P 500 significantly over the past year, with a return of 83.25% compared to the S&P's 17.14%. Overall, the current technical stance is bullish with strong momentum indicators, despite some mixed signals in the KST.

View full answer

Is BrightSpring Health Services, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, BrightSpring Health Services, Inc. is considered undervalued with a P/E ratio of 37, an EV to EBITDA of 12.65, and a PEG ratio of 0.12, outperforming the S&P 500 with a year-to-date return of 74.57%.

As of 17 October 2025, the valuation grade for BrightSpring Health Services, Inc. moved from expensive to attractive, indicating a shift towards being undervalued. The company appears to be undervalued based on several key ratios, including a P/E ratio of 37, an EV to EBITDA of 12.65, and a PEG ratio of 0.12, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, BrightSpring's P/E ratio of 37.784 is slightly higher than the industry average, while its EV to EBITDA of 13.2063 is more favorable, indicating better valuation metrics. Notably, the company has outperformed the S&P 500 with a year-to-date return of 74.57% compared to the index's 13.30%, reinforcing the attractiveness of its current valuation.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a growth in Net Profit of 313.63%, the company declared Very Positive results in Sep 25

  • The company has declared positive results for the last 2 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 392.42 MM
  • INTEREST COVERAGE RATIO(Q) Highest at 382.56
  • ROCE(HY) Highest at 4.25%
2

With ROE of 6.85%, it has a attractive valuation with a 3.10 Price to Book Value

3

High Institutional Holdings at 100%

4

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7,405 Million (Small Cap)

stock-summary
P/E

45.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.33

stock-summary
Return on Equity

8.35%

stock-summary
Price to Book

4.07

Revenue and Profits:
Net Sales:
3,334 Million
(Quarterly Results - Sep 2025)
Net Profit:
37 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.39%
0%
14.39%
6 Months
62.04%
0%
62.04%
1 Year
107.52%
0%
107.52%
2 Years
332.4%
0%
332.4%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

BrightSpring Health Services, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
19.62%
EBIT Growth (5y)
15.27%
EBIT to Interest (avg)
1.26
Debt to EBITDA (avg)
4.73
Net Debt to Equity (avg)
1.50
Sales to Capital Employed (avg)
2.40
Tax Ratio
20.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
9,390.06%
ROE (avg)
868.50%

Valuation key factors

Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
3.10
EV to EBIT
23.12
EV to EBITDA
14.87
EV to Capital Employed
1.86
EV to Sales
0.66
PEG Ratio
0.11
Dividend Yield
NA
ROCE (Latest)
8.05%
ROE (Latest)
6.85%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
No Trend
Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 47 Schemes (43.03%)

Foreign Institutions

Held by 82 Foreign Institutions (8.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 5.92% vs 9.37% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 341.18% vs -7.61% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,334.10",
          "val2": "3,147.70",
          "chgp": "5.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "146.30",
          "val2": "123.00",
          "chgp": "18.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "38.20",
          "val2": "38.80",
          "chgp": "-1.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-17.70",
          "val2": "-32.60",
          "chgp": "45.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "37.50",
          "val2": "8.50",
          "chgp": "341.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "31.60%",
          "val2": "25.80%",
          "chgp": "0.58%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 27.65% vs 14.32% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 86.93% vs -189.30% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11,266.50",
          "val2": "8,826.20",
          "chgp": "27.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "509.20",
          "val2": "392.10",
          "chgp": "29.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "228.40",
          "val2": "324.60",
          "chgp": "-29.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-111.10",
          "val2": "-42.60",
          "chgp": "-160.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.50",
          "val2": "-156.80",
          "chgp": "86.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.10%",
          "val2": "21.50%",
          "chgp": "0.56%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
3,334.10
3,147.70
5.92%
Operating Profit (PBDIT) excl Other Income
146.30
123.00
18.94%
Interest
38.20
38.80
-1.55%
Exceptional Items
-17.70
-32.60
45.71%
Consolidate Net Profit
37.50
8.50
341.18%
Operating Profit Margin (Excl OI)
31.60%
25.80%
0.58%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 5.92% vs 9.37% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 341.18% vs -7.61% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
11,266.50
8,826.20
27.65%
Operating Profit (PBDIT) excl Other Income
509.20
392.10
29.86%
Interest
228.40
324.60
-29.64%
Exceptional Items
-111.10
-42.60
-160.80%
Consolidate Net Profit
-20.50
-156.80
86.93%
Operating Profit Margin (Excl OI)
27.10%
21.50%
0.56%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 27.65% vs 14.32% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 86.93% vs -189.30% in Dec 2023

stock-summaryCompany CV
About BrightSpring Health Services, Inc. stock-summary
stock-summary
BrightSpring Health Services, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available